View Exam | PowerPak

1. Which of the following is true regarding the medical burden of untreated severe veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients undergoing hematopoietic stem cell transplantation (HSCT)?

A. Similar rates of mortality with moderate and severe VOD/SOS B. High rates of mortality, often in excess of 90% C. High rates of mortality, reported to be approximately 40% to 50% D. No differences in mortality between mild, moderate, or severe VOD/SOS

2. Assume you are reviewing the treatment history of a patient with acute lymphoblastic leukemia (ALL); the presence of which of the following therapies would lead you to consider this patient at high risk for the development of VOD/SOS?

A. Blinatumomab B. Dasatinib C. Rituximab (in combination with hyperfractionated cyclophosphamide, vincristine, and doxorubicin [hyperCVAD]) D. Inotuzumab ozogamicin

3. You are managing an adult patient with myelofibrosis who exhibits right upper quadrant pain and jaundice at day +7 after allogeneic transplant; 9 days post-transplant, his bilirubin has doubled to 7 mg/dL (in a roughly 24 hour period), with a weight increase of 6% and declining renal function. Ultrasound imaging shows reversal of portal venous flow. What diagnosis and treatment strategy would you select?

A. Severe VOD; treat with supportive care B. Moderate VOD; monitor for 1 week then treat with supportive care + defibrotide, if symptoms worsen C. Moderate VOD; treat with supportive care + defibrotide D. Severe VOD; treat with supportive care + defibrotide

4. Which of the following strategies is the most appropriate when a patient develops severe VOD/SOS, initiates therapy with defibrotide, and experiences an episode of bleeding?

A. No intervention necessary B. Hold therapy, treat bleed, resume at same dose once the patient is stable/bleeding has stopped C. Discontinue therapy, treat bleed, switch to ursodiol once the patient is stable/bleeding has stopped D. Permanently discontinue therapy

5. Which of the following pretransplant strategies used for graft-versus host disease (GVHD) prophylaxis is associated with the greatest risk for post-HSCT VOD/SOS?

A. Sirolimus B. Calcineurin inhibitors (CNIs) C. CNI + sirolimus D. No preventive strategies for GVHD associated with high risk of VOD

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is true regarding the medical burden of untreated severe veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients undergoing hematopoietic stem cell transplantation (HSCT)?

2. Assume you are reviewing the treatment history of a patient with acute lymphoblastic leukemia (ALL); the presence of which of the following therapies would lead you to consider this patient at high risk for the development of VOD/SOS?

4. Which of the following strategies is the most appropriate when a patient develops severe VOD/SOS, initiates therapy with defibrotide, and experiences an episode of bleeding?

5. Which of the following pretransplant strategies used for graft-versus host disease (GVHD) prophylaxis is associated with the greatest risk for post-HSCT VOD/SOS?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is true regarding the medical burden of untreated severe veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients undergoing hematopoietic stem cell transplantation (HSCT)?

2. Assume you are reviewing the treatment history of a patient with acute lymphoblastic leukemia (ALL); the presence of which of the following therapies would lead you to consider this patient at high risk for the development of VOD/SOS?

4. Which of the following strategies is the most appropriate when a patient develops severe VOD/SOS, initiates therapy with defibrotide, and experiences an episode of bleeding?

5. Which of the following pretransplant strategies used for graft-versus host disease (GVHD) prophylaxis is associated with the greatest risk for post-HSCT VOD/SOS?

« Return to Activity

Customers who Purchased
this Activity also Purchased